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Abstract
Background: Bronchiolitis is a lower respiratory tract infection that is most common in the pediatric
population, and is the major cause of hospitalizations for patients in their first year of life. Despite the
prevalence of this disease, a consensus for optimal treatment is elusive. Although numerous studies have
addressed dexamethasone or epinephrine alone, the combination is not well established. The optimal
therapeutic management of bronchiolitis is still controversial. The objective of this literature review is to
determine the effectiveness of the combination of dexamethasone and epinephrine in pediatric patients with
bronchiolitis.
Methods: A systematic review from 1990 to the present of English-language published literature was
conducted using MEDLINE, CINAHL, and ISI Web of Science, Evidence Based Medicine Reviews Multifile,
and Google Scholar using keywords bronchiolitis, and dexamethasone, and epinephrine. Articles of original
research examining outcomes of the management of bronchiolitis with dexamethasone and epinephrine
versus placebo and epinephrine versus placebo. Meta-analyses and case reports or series were excluded.
Fifteen studies, three of which compared combination therapy of dexamethasone and epinephrine therapy to
placebo were retrieved and analyzed for quality and significant results.
Results: The three studies that were reviewed indicate that there is a significant positive effect of the
combination therapy of dexamethasone and epinephrine in the management of bronchiolitis. There is a
synergistic effect between dexamethasone and epinephrine that has been shown to decrease the rate of
hospital admission and length of hospital stay in the three studies included in this systematic review.
Discussion: Current guidelines suggest tailoring the treatment of bronchiolitis based on the presentation of
symptoms. Although the American Academy of Pediatrics has produced a manuscript for the diagnosis and
management of bronchiolitis, it gives an overview of available treatment modalities without a consensus on
optimal treatment. Additional prospective research efforts, perhaps even larger, multi-center, randomized
placebo-controlled trials, are needed to quantify and qualify possible risks of combination therapy of
dexamethasone with epinephrine in the pediatric population. Such work should be on large population with a
broader age range (2 months to 5 years), and should include patients who are both first-time wheezers, and
recurrent wheezers. Lastly, research should be performed on the long-term effects of corticosteroid therapy in
the pediatric population.
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Abstract   
 
 
Background:  Bronchiolitis is a lower respiratory tract infection that is most common in the pediatric 
population, and is the major cause of hospitalizations for patients in their first year of life.  Despite the 
prevalence of this disease, a consensus for optimal treatment is elusive. Although numerous studies 
have addressed dexamethasone or epinephrine alone, the combination is not well established. The 
optimal therapeutic management of bronchiolitis is still controversial. The objective of this literature 
review is to determine the effectiveness of the combination of dexamethasone and epinephrine in 
pediatric patients with bronchiolitis.  
Methods:  A systematic review from 1990 to the present of English-language published 
literature was conducted using MEDLINE, CINAHL, and ISI Web of Science, Evidence Based 
Medicine Reviews Multifile, and Google Scholar using keywords bronchiolitis, and dexamethasone, 
and epinephrine. Articles of original research examining outcomes of the management of bronchiolitis 
with dexamethasone and epinephrine versus placebo and epinephrine versus placebo. Meta-analyses 
and case reports or series were excluded. Fifteen studies, three of which compared combination 
therapy of dexamethasone and epinephrine therapy to placebo were retrieved and analyzed for quality 
and significant results. 
Results:  The three studies that were reviewed indicate that there is a significant positive effect of the 
combination therapy of dexamethasone and epinephrine in the management of bronchiolitis. There is a 
synergistic effect between dexamethasone and epinephrine that has been shown to decrease the rate of 
hospital admission and length of hospital stay in the three studies included in this systematic review.  
Discussion: Current guidelines suggest tailoring the treatment of bronchiolitis based on the 
presentation of symptoms.  Although the American Academy of Pediatrics has produced a manuscript 
for the diagnosis and management of bronchiolitis, it gives an overview of available treatment 
modalities without a consensus on optimal treatment. Additional prospective research efforts, perhaps 
even larger, multi-center, randomized placebo-controlled trials, are needed to quantify and qualify 
possible risks of combination therapy of dexamethasone with epinephrine in the pediatric population.  
Such work should be on large population with a broader age range (2 months to 5 years), and should 
include patients who are both first-time wheezers, and recurrent wheezers.  Lastly, research should be 
performed on the long-term effects of corticosteroid therapy in the pediatric population. 
Keywords:  Dexamethasone, Epinephrine, Bronchiolitis 
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The Effectiveness of Dexamethasone as Adjunctive Therapy to Racemic Epinephrine in the Pediatric 
Patient with Bronchiolitis 
 
 
BACKGROUND 
Overview 
 Bronchiolitis is the most prevalent lower respiratory tract infection in childhood, although most 
children experience it only in its mild forms.{{51 Lieberthal,Allan S. 2006}}  It  most often has a viral 
etiology, with the leading virus being respiratory syncytial virus (RSV), which is most prevalent during 
the winter and fall seasons.{{65 Piedra, Pedro 2009}} The diagnosis is made by patient history and 
physical examination.  It is characterized, by most clinicians, as a constellation of symptoms: viral 
upper respiratory prodrome followed by increased respiratory effort and wheezing, fever, coryza, 
cough, expiratory wheezing, and respiratory distress{{65 Piedra, Pedro 2009}}{{51 Lieberthal,Allan 
S. 2006}} Severe disease is characterized by persistently increased respiratory effort (increased 
respiratory rate and decreased pulse oximetry), apnea, or the need for medical interventions such as 
fluid therapy, supplemental oxygen, or mechanical ventilation. {{51 Lieberthal,Allan S. 2006}}{{66 
Glover, Mark L}}A viral nasal wash via nasopharyngeal swab and ELISA may be performed to 
identify the causative pathogen; however, generally, this does not change the treatment or management 
course.{{51 Lieberthal,Allan S. 2006}}  
 Bronchiolitis is an infectious disease that affects the muco-epithelial lining of the 
bronchiole.{{66 Glover, Mark L; 51 Lieberthal,Allan S. 2006}} This causes pathophysiological 
changes such as local edema, a large amount of thick secretions in the airway lumen, mucous plugging, 
and increased intraluminal pressure, making it difficult to breathe. In adults bronchiolitis is a mild viral 
infection that induces inflammation of the bronchioles with minimal effect. What is merely a mild 
infection in adults, is more critical in the Pediatric population, inducing a more severe disease of the 
airway lining.  The respiratory distress assessment index (RDAI), is a clinical assessment tool that is 
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used in most bronchiolitis studies to assess the severity of the disease. It rates wheezing and respiratory 
distress on a scale from 0-17, with higher scores indicating more severe illness.{{48 Plint,Amy C. 
2009}} 
Epidemiology 
 Bronchiolitis is the most common lower respiratory tract infection, afflicting 11-12% of the 
pediatric population within the first year of life {{43 Shay,D.K. 1999}}. Approximately 1-2% of 
affected infants under the age of one may require hospitalization.{{43 Shay,D.K. 1999}} According to 
a study published by the Journal of the American Medical Association, during a 17-year study period, 
an estimated 1.65 million hospitalizations for bronchiolitis occurred among children under five years, 
accounting for 7 million inpatient stays. {{43 Shay,D.K. 1999}} In previously healthy infants who are 
older than six months and require hospitalization for the management of bronchiolitis, the average 
length of hospitalization is three days {{43 Shay,D.K. 1999}}. Despite the high prevalence of 
bronchiolitis, there is a lack of consensus regarding the treatment and management of the disease. In 
addition to morbidity and mortality during the acute course of bronchiolitis, infants hospitalized with 
bronchiolitis are more likely to have respiratory issues as older children, wheezing in particular, when 
compared to those who did not have severe disease. {{46 Kajosaari,M. 2000}}{{64 Martinez,F.D. 
2003}}Treatment for bronchiolitis is generally supportive, antipyretics, supplementary oxygen, and 
fluid therapy.  The optimal treatment for acute bronchiolitis still remains controversial.  
Current Treatment of Bronchiolitis 
Supportive care 
 Treatments for and management of bronchiolitis can be divided into two categories, either 
specific or symptomatic.  Specific treatment refers to an antiviral therapy for positive RSV 
bronchiolitis.{{54 Bordley,W.C. 2004}}  Symptomatic treatment with antipyretics, supplemental 
oxygen, fluid therapy, and close monitoring are the most common.{{59 Abul-Ainine,A. 2002}} 
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Supportive care in both the inpatient and outpatient settings, includes respiratory support and  
appropriate fluid maintenance.{{66 Glover, Mark L}}{{59 Abul-Ainine,A. 2002}} Respiratory 
support may be administered based on patient’s need, in order to maintain arterial oxygen saturation 
above 90-92%. {{51 Lieberthal,Allan S. 2006; 32 Mallory,Michael D. 2003; 61 Milner,A.D. 1989}} 
The American Academy of Pediatrics (AAP) guidelines recommends oxygen supplement in oxygen 
saturation readings of less than 90% {{51 Lieberthal,Allan S. 2006}}. Fluid resuscitation via the 
parenteral route may also be necessary to avoid dehydration.  Patients with bronchiolitis have 
increased metabolic demand related to fever, tachypnea, and respiratory distress, and therefore, 
electrolyte status should also be monitored.{{66 Glover, Mark L; 51 Lieberthal,Allan S. 2006}}  
Along with supportive care, repeated clinical assessment (patient monitoring) should be done to assess 
the patient’s respiratory status. Hospitalized patients should have continuous monitoring of basic vital 
signs including but not limited to, respiratory rate, heart rate, and oxygen saturation.  
Bronchodilators 
 Studies performed on inpatients with bronchiolitis, have not shown positive clinical progress 
that would recommend for routine albuterol. {{37 Klassen,T.P. 1997; 42 Schuh,S. 2002}} Several 
studies have compared epinephrine to albuterol (salbutamol) or epinephrine to placebo.{{58 Patel,H. 
2002; 49 Walsh,Paul 2008}} Clinically, racemic epinephrine has been shown to be slightly more 
effective than albuterol, and it may be postulated that the improvement is related to the α effect of the 
medication. {{51 Lieberthal,Allan S. 2006}} In a meta-analysis studying the effectiveness of 
epinephrine by Hartling et al{{56 Hartling,L. 2003}}, it was concluded that “[t]here is insufficient 
evidence to support the use of epinephrine for the treatment of bronchiolitis among inpatients. There is 
some evidence to suggest epinephrine may be favorable to salbutamol and placebo among outpatients.” 
Epinephrine is an effective, fast-acting bronchodilator that stimulates α and β1 and β2 receptors. It may 
be injected subcutaneously or inhaled. Sympathomimetics such as epinephrine relax the airway smooth 
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muscle and inhibit release of bronchoconstricting mediators from mast cells.  {{58 Patel,H. 
2002}}Additionally, they may also inhibit microvascular leakage and increase mucociliary transport 
by increasing ciliary activity. There are a few adverse side effects that may occur because of the 
adrenoreceptor agonist mechanism of action. Maximum effect of bronchodilation, is seen after 15 
minutes of therapy and lasts 60-90 minutes. {{65 Piedra, Pedro 2009}} 
 Although bronchodilators have not shown to be clinically useful in viral bronchiolitis, it is also 
difficult to distinguish between a patient with a propensity to develop asthma, and a patient with viral 
bronchiolitis. Both of these have disease courses present similarly with wheezing and respiratory 
distress. Therefore, it may be necessary to do a trial of inhaled bronchodilators, which may be 
continued if there is clinical improvement by objective standards. Selective adrenoreceptor agonist 
drugs from the β-2 selective class, predominantly albuterol, are structurally different than epinephrine 
in having a larger substitution on the amino group and in the position of the hydroxyl groups on the 
aromatic ring. {{66 Glover, Mark L}}{{65 Piedra, Pedro 2009}}They are effective after inhaled or 
orally administered and have a long duration of action. Maximum effect of bronchodilation, is within 
15-30 minutes of therapy and lasts for 3-4 hours. {{66 Glover, Mark L}}The clinical AAP guidelines 
state that bronchodilators should not be used routinely in the management of bronchiolitis {{51 
Lieberthal,Allan S. 2006}}. 
Corticosteroids 
 Inhaled dexamethasone, prednisolone, budesonide, which belong to the class of 
glucocorticoids, alone are not used routinely in the management of bronchiolitis. {{51 Lieberthal,Allan 
S. 2006}}Corticosteroids are effective anti-inflammatory drugs that have proven to clinically improve 
asthma, however, the effectiveness in bronchiolitis is not well established. {{62 Roosevelt,Genie 
1996}}A randomized trial of nebulized budesonide versus placebo in 161 infants hospitalized with 
RSV bronchiolitis did not demonstrate any significant decrease in morbidity or length of disease 
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course between the two treatment groups. {{47 Cade,A. 2000}} Dexamethasone sodium is freely 
soluble in water, slightly soluble in lipid, and is a strong anti-inflammatory agent. {{66 Glover, Mark 
L}}  
Purpose of Study 
 Although bronchiolitis is not a major cause of mortality in the pediatric population, RSV 
bronchiolitis may have a correlation with subsequent bronchial hyper-reactivity, recurrent obstructive 
bronchitis, and asthma symptoms.{{46 Kajosaari,M. 2000}}  Pathophysiologically, the combination of 
the innately smaller airways, and the obstruction due to inflammatory mediators, indicates that 
systemic corticosteroids may play a role in the management of acute bronchiolitis and shorten the 
disease process. Currently, the effectiveness of dexamethasone and epinephrine combination therapy 
has not yet been identified as a standard of treatment for acute bronchiolitis. The purpose of this paper 
is to perform a systematic review and determine whether or not dexamethasone as adjunctive therapy 
to racemic epinephrine, is effective in pediatric bronchiolitis patients by looking at the decrease in the 
rate of hospital admission and the length of hospital stay.  The basis of treatment is generally case by 
case, therefore it is important for providers to stay updated on the most recent clinical studies regarding 
bronchiolitis treatment and management.  
Clinical Question 
 The question of the effectiveness of dexamethasone as adjunctive therapy to epinephrine is an 
important one because the lack of information regarding the success. There is no standard therapy for 
the management of bronchiolitis.  Recommendations have been graded and printed in a manuscript by 
the American Academy of Pediatrics, but the question of the effectiveness of this combination therapy 
still remains.  
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METHODS 
Search Strategy 
 In order to design a detailed and thorough search of scientific literature, more than three search 
engines were used. An exhaustive literature search was performed using MEDLINE, CINAHL, ISI 
Web of Science, Evidence Based Medicine Reviews Multifile, and Google Scholar using keywords 
bronchiolitis, dexamethasone, and epinephrine. Articles of original research examining outcomes of 
the management of bronchiolitis with dexamethasone and epinephrine versus placebo and epinephrine 
versus placebo were included in the research. Meta-analyses and case reports or series were excluded. 
Fifteen studies were reviewed from the entire systematic review.  Three of the fifteen studies  met the 
inclusion criteria, by comparing dexamethasone and racemic epinephrine versus placebo, and, were 
retrieved and analyzed for quality and significant results. Subsequently, an analysis of bibliographic 
entries from the three articles, generated additional studies for consideration. 
Inclusion/Exclusion Criteria 
 The search was also limited to English-language published studies of the pediatric population 
after 1990.  Only randomized controlled studies were included. Studies of pharmaceutical therapy 
other than dexamethasone or epinephrine were excluded. Taking into account these exclusions, three 
articles were appraised using the Jadad scoring guideline.  The Jadad scoring guideline was used as a 
guideline for quality and validity of each article. Articles that received a score greater than three were 
included in this review. As such, all three articles remained valid by score. See Table 1 for a 
description of the Jadad criteria.  
 
RESULTS 
 After an extensive search, a total of three articles which met all of the inclusion and exclusion 
criteria were examined (See Tables 1 and 2 for summary of articles reviewed. The sample sizes of the 
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studies are 800 infants, 69 infants, and 61 infants. Ages of the patients ranged from 2 months- 21 
months.  All studies that are included in this review are randomized controlled trials. All studies were 
also double-blinded, and compared the combination therapy of dexamethasone with epinephrine versus 
placebo.  Each study measured outcome with various objective measuring standards, and each utilized 
the respiratory distress assessment index (RDAI) score value. {{51 Lieberthal,Allan S. 2006}} The 
RDAI is the most widely used score and is reliable with respect to scoring, but it has not been validated 
for clinically predictive value in bronchiolitis. {{51 Lieberthal,Allan S. 2006}}{{49 Walsh,Paul 
2008}}The shortest study was 5 days in length, and the longest study was over 3 months. Bronchiolitis 
was defined as the first episode of wheezing associated with signs of an upper respiratory tract 
infection during the peak RSV season in Kuyucu et al{{40 Kuyucu,S. 2004}} and Plint et al.{{48 
Plint,Amy C. 2009}}   
 In a study of 69 infants published by Pediatrics International, Kuyucu at al{{40 Kuyucu,S. 
2004}}, conducted a study in a pediatric outpatient clinic and the emergency department at Mersin 
University during the winter months to determine the additive effects of dexamethasone in L-
epinephrine or salbutamol therapy in patients with bronchiolitis. Bronchiolitis is defined by the study 
as first time wheezing associated with clinical evidence of a viral infection in infants. This was a 
randomized, double-blind, placebo-controlled study. This study received a Jadad score of 5. Patients 
were eligible for the study if they were aged between 2-21 months, admitted for a first episode of 
wheezing, clinical findings compatible with diagnosis of acute bronchiolitis, and a RDAI score of ≥ 4. 
Patients were excluded from the study if they had a personal history of wheezing, a previous treatment 
with bronchodilators, a previous diagnosis of asthma or allergic bronchitis, a personal history of atopic 
dermatitis or allergic rhinitis, any chronic cardiac or pulmonary disease, any steroid treatment within 
the previous 2 weeks, signs of severe respiratory disease (pulse rate ≥ 200 beats/min, respiratory rate ≥ 
100 breaths/min, RDAI score of ≥ 15, profound lethargy, clinical and/or radiological evidence of 
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bacterial infection, and family or parental history of asthma or atopic disease.  A thorough history was 
taken and a complete physical examination was performed.{{40 Kuyucu,S. 2004}}   
 Eligible patients were divided into three groups. Group 1 was treated with 3 mg of nebulized L-
Epinephrine and fifteen minutes following the nebulized L-Epinephrine, participants in group 1 
received dexamethasone 0.6 mg/kg intramuscularly. Group 2 received salbutamol 0.15 mg/kg, and 
fifteen minutes following the treatment, participants received dexamethasone 0.6 mg/kg 
intramuscularly. Group 3 received nebulized L-epinephrine and placebo whereas group 4 received 
salbutamol and placebo. The clinical outcome measures were heart rate, respiratory rate, and RDAI 
score. Clinical assessments were taken at 30, 60, 90, and 120 minutes after the first treatment. If 
patients did not improve their RDAI score by 4 points by 120 minutes, an additional treatment of the 
same medication was administered. Patients were also followed up at 24 hours and finally finished at 5 
days post-treatment. Patients were then followed up in 2 months to determine the prevalence of 
respiratory complaints such as development of exercise induced wheezing and continued 
wheezing.{{40 Kuyucu,S. 2004}}   
 Kuyucu et al{{40 Kuyucu,S. 2004}} concluded that a single dose of intramuscular 
dexamethasone in addition to L-epinephrine or salbutamol therapies did result in better outcome 
measures than placebo in the late phase (fifth day) of mild to moderate bronchiolitis attack. At day 5, 
in groups 1 and 2, both groups that received intramuscular dexamethasone, patients demonstrated a 
significantly lower RDAI score when compared to groups 3 and 4 who had received placebo. Fifth day 
RDAI score in group 1 was significantly lower than group 3 and group 4 (P = 0.01 and P = 0.00). The 
fifth day score of group 2 was also appreciably lower than group 4 (P = 0.01), but not statistically 
significant when compared to group 3 (P = 0.09). The fifth day RDAI scores between groups 1and 2 
were not statistically significant, which established that there was no difference in clinical outcome 
between epinephrine and salbutamol. With these results, this study concludes that a single dose of 
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dexamethasone added to either nebulized L-epinephrine or salbutamol treatments, resulted in a better 
clinical outcome measures than treatment with bronchodilators alone, on the fifth day after treatment 
of mild to moderate bronchiolitis.{{40 Kuyucu,S. 2004}}  
 Bentur et al{{52 Bentur,L. 2005}} studied 61 infants aged 3 to 12 months with bronchiolitis. 
The patients were similar in demographics, except for six infants in group 1 and seven infants in group 
2 who were born prematurely.  Prematurity was defined at gestational age < 32 weeks.  There were no 
other significant differences between the groups in age, demographic data, breastfeeding, weight, 
oxygen saturation, and clinical score at admission. The study was a double-blinded, placebo-controlled 
study.  This study received a Jadad score of 4 because there was no explanation of patient withdrawal 
or drop out (if any). In Table 1 of this article, there is a description of the number of infants enrolled in 
the study, however the 3 month follow-up is expressed as ± SEM, yet they are not accounted for. 
Patients were included in they had a first episode of wheezing and dyspnea, positive RSV antigen 
detected by ELISA, and parental signature of informed consent. Patients were excluded from the study 
if they had a previous treatment with systemic steroids, inhaled β2 agonist or inhaled steroids prior to 
admission, or if they suffered from bronchopulmonary dysplasia, cystic fibrosis, and congenital heart 
disease.{{52 Bentur,L. 2005}}  
 There were two study groups. Group 1 was treated with 0.25mg inhaled dexamethasone with 
1mL epinephrine, and group 2 was treated with 0.5 mL 0.9% saline with 1mL epinephrine. The 
therapy was administered through a face mask every six hours, and continued until the patient was 
discharged.  The clinical outcome was measured by objective variables including: respiratory rate, 
heart rate, oxygen saturation, and clinical status every 8 hours. Each variable was given a point value 
to establish a point system similar to RDAI. Supplemental oxygen therapy was provided, during 
intervals for a patient who had an oxygen saturation of < 92%, given by pulse oximetry. Additionally, 
if the respiratory rate was > 60 breaths/minute, oral feeding was stopped and intravenous fluid was 
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started. The clinical outcome was measured by the length of in-patient hospital stay.{{52 Bentur,L. 
2005}} 
 The result of this study found that the difference in the length of hospitalization was especially 
notable among infants from group 1 who were born prematurely. This particular patient group had a 
shorter hospitalization period (6.5 ± 1.7d, mean ± SEM) compared with the prematurely born children 
in group 2 (9.1 ± 1.9) (p < 0.018).  An analysis of full-term infants demonstrated the same trend.  The 
cumulative proportion of in-patient stay of full term and pre-term infants was lower in the 
dexamethasone group than in the placebo group, most noticeably in days 5 and 6 post-hospitalization 
(p < 0.038) . This study concluded from these values that inhaled dexamethasone therapy in addition to 
inhaled epinephrine, may decrease the overall length of in-patient hospital stay, especially in the subset 
of prematurely born infants.{{52 Bentur,L. 2005}} 
  The last study was the largest study, and was conducted by Plint et al {{48 Plint,Amy C. 
2009}}.  Plint et al{{48 Plint,Amy C. 2009}} studied the effectiveness of combining nebulized 
epinephrine with corticosteroids. The study design was a multi-center, double-blind, placebo-
controlled trial that included 800 infants (6 weeks to 12 months of age) with bronchiolitis, who were 
seen in the pediatric emergency department.  This study received a Jadad score of 5. Patients were 
recruited December through April, during the bronchiolitis season, at eight Canadian pediatric 
emergency departments, for a total of 3 years.  Bronchiolitis, was defined in this study, as the first 
episode of wheezing associated with signs of upper respiratory tract infection during the peak RSV 
season and was diagnosed by a physician. Once the diagnosis was made, an RSV nasal pharyngeal 
sample was taken for testing. Participants qualified for the study if: they had a score of 4-15 according 
to the RDAI. Participants were excluded from the study if: they received bronchodilator therapy in the 
ED before being assessed by the research nurse, infants had received oral or inhaled corticosteroids 
within the previous 2 weeks, infants had a previous episode of wheezing or diagnosis of asthma, they 
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had previous bronchodilator use, they had any chronic cardiopulmonary disease or immunodeficiency, 
and infants who were in severe respiratory distress.  Additionally, infants who were born before 37 
weeks gestational age with a corrected age of less than 6 weeks at presentation were also excluded.  
Finally, patients were excluded if there was a severe insurmountable obstruction to communication 
with parents or guardians. Prior to the treatment if patients had an oxygen saturation of < 92% at room 
air they received supplemental oxygen, and any child with a fever (rectal temperature > 38°C) received 
acetaminophen (15 mg/kg).{{48 Plint,Amy C. 2009}}   
 Patients were then randomly divided into four separate study groups. Group 1 received 
nebulized epinephrine plus oral dexamethasone, group 2 received nebulized epinephrine plus oral 
placebo, group 3 received nebulized placebo plus oral dexamethasone, and group 4 received nebulized 
placebo plus oral placebo. The patients were given two nebulization treatments at 30 minutes apart, 
with a suspension of 3ml of generic epinephrine in a 1:1000 solution or an equivalent volume of saline 
(placebo).  The oral treatments of dexamethasone were based on a study by Schuh et al, {{48 
Plint,Amy C. 2009}} {{42 Schuh,S. 2002}} and consisted of 1.0 mg of dexamethasone per kilogram 
of body weight (maximum dose of 10mg) or placebo, given after the first nebulized treatment in the 
emergency department, followed by five once-daily doses of dexamethasone (0.6 mg/kg; maximum 
daily dose, 10mg) or placebo.{{48 Plint,Amy C. 2009}}  
 Throughout the study, the patient’s RDAI score, respiratory rate, heart rate, and oxygen 
saturation at room air, were documented. These measurements were taken between the two 
nebulizations and again at 30, 60, 90, 120, 180, and 240 minutes. Patients were followed up to 22 days 
past enrollment. The primary outcome of this study was hospital admission up to 7 days after 
enrollment, which was determined through telephone follow-up and chart review. Secondary outcomes 
were changes in heart rate, respiratory rate, RDAI score, and oxygen saturation from baseline, and 
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measured at 30, 60, 90, 120, and 240 minutes. Secondary outcomes of the duration and severity of 
bronchiolitis were determined by telephone follow-up. {{48 Plint,Amy C. 2009}} 
 The results of this study demonstrated that the relative risk of admission by day 7 in group 1 
(epinephrine and dexamethasone) and group 4 (placebo) was 0.65 (95% confidence interval, 0.45 to 
0.95; p = 0.02 and p = 0.07 for the unadjusted and adjusted analyses, respectively). From these values, 
it can be calculated that 11 infants would need to be treated in order to prevent one hospital admission 
(NNT). Additionally, this study demonstrates that epinephrine or dexamethasone treatment alone 
(groups 2 and 3), do not reduce the rate of hospital admission in comparison to placebo (p = 0.87 and p 
= 0.52, respectively for the unadjusted analyses.  
 This study concluded that there was an unexpected synergy between dexamethasone and 
epinephrine such that this combined therapy, when compared to placebo, reduced the rate of hospital 
admission in the 7 days after study enrollment by 9 percentage points, with a relative risk reduction of 
35%. These results were modified by RSV status, presence or absence by history of atopy, or the 
severity or the duration of illness. The outcome of combining dexamethasone and epinephrine is most 
apparent in the first 3 days after study enrollment. Secondary outcomes were also improved by the 
combination therapy. Infants in group 1 were discharged earlier from medical care and resumed quiet 
breathing and normal feeding sooner than infants in group 4. {{48 Plint,Amy C. 2009}} 
 
DISCUSSION 
       The main goal of this literature review is to examine, by evaluating and appraising the most 
relevant and current medical literature, the effectiveness of the combination therapy of dexamethasone 
and epinephrine, in decreasing hospital admission rates or length of hospital stay in pediatric patients 
with bronchiolitis. Of the three articles that were appraised in this literature review, the evidence was 
conclusive that there is a statistically significant relationship between dexamethasone with epinephrine 
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therapy in decreasing the rate of hospital admission and the length of hospital stay.{{52 Bentur,L. 
2005; 40 Kuyucu,S. 2004; 48 Plint,Amy C. 2009}} All three articles shared a common quality; they 
were randomized controlled studies that compared the combination therapy of dexamethasone and 
epinephrine with placebo. Furthermore, all three studies used the RDAI score as either, part of the 
clinical assessment, or as the clinical outcome measurement.  
      Currently, there is no standard of care for the treatment of bronchiolitis. Infants with bronchiolitis 
have been treated with corticosteroids because this class is well known for anti-inflammatory effects 
on multiple cellular levels.{{66 Glover, Mark L}}  Health care providers have used corticosteroids in 
infants in part, because of their effective therapy in the pediatric population for asthma and croup. The 
studies that are reviewed in this paper address the use of corticosteroids in decreasing the morbidity 
due to bronchiolitis.  Patients in each study group had similar baseline characteristics (age, 
demographics, RDAI scores), and were otherwise healthy infants ranging from 2 months to 21 months. 
{{52 Bentur,L. 2005; 40 Kuyucu,S. 2004; 48 Plint,Amy C. 2009}}Bentur et al{{52 Bentur,L. 2005}}, 
was the only exception because this study included pre-term infants (< 32 weeks gestational age) in the 
sample population. Further limitations of each study are discussed below. 
Limitations of Study 
      The results of this systematic literature review should be interpreted in light of several limitations. 
In Kuyucu et al{{40 Kuyucu,S. 2004}}, one of the limitations is that it was a small study (69 
participants), with a small number of patients in the placebo groups. This study, however, did take into 
account the social history of the child, tobacco exposure, sibling history, and duration of illness. No 
RSV swab was taken to identify the causative agent. The diagnosis of bronchiolitis was made 
clinically, with no distinction between asthmatic wheezer and bronchiolitis.{{40 Kuyucu,S. 2004}} 
Bentur et al{{52 Bentur,L. 2005}} was also limited by having a small study with only 61 participants. 
Bentur et al{{52 Bentur,L. 2005}} did take a RSV antigen swab detected by ELISA; each participant 
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did have a positive RSV antigen. Consequently, this study is specifically studying RSV bronchiolitis. 
In the Plint et al{{48 Plint,Amy C. 2009}} study, an RSV antigen swab was not taken.  
      These studies defined bronchiolitis as an episode of first time wheezing associated with clinical 
evidence of a viral infection. It is difficult to distinguish the etiology of wheezing as either intrinsic or 
triggered by a myriad other assaults. Accordingly, effective treatments for infants with bronchiolitis 
have proven to be elusive.  
      The studies by Plint et al{{48 Plint,Amy C. 2009}} and Kuyucu et al{{40 Kuyucu,S. 2004}} were 
conducted during the winter season which is peak RSV season, whereas Bentur et al{{52 Bentur,L. 
2005}} was done continuously from September 2002-March 2003 and, as part of the inclusion criteria, 
all participants were tested for a positive RSV antigen via ELISA nasopharyngeal swab.  
       In general, the articles that are included in this review used similar research methods in obtaining 
their sample population, however treatment modalities varied slightly.  Kuyucu et al{{40 Kuyucu,S. 
2004}} administered one single intramuscular dose of dexamethasone added to nebulized L-
epinephrine, whereas Bentur et al{{52 Bentur,L. 2005}} administered 0.25mg dexamethasone with 
1ml epinephrine via nebulizer every six hours until discharge. The study participants of Plint et al{{48 
Plint,Amy C. 2009}} received two treatments of nebulized epinephrine, which consisted of 3ml of 
epinephrine in a 1:1000 solution per treatment, and a total of six oral doses of dexamethasone (1.0mg/ 
kg of body weight in the emergency department and 0.6 mg/kg for an additional five days).  
      Although the conclusion of these three articles is that there is a statistically significant relationship 
between the combination therapy (dexamethasone and epinephrine) and decreasing hospital admission 
rates and/or the length of inpatient hospital stay, the outcome measurements varied in each study.  The 
variability in dosing and administration of dexamethasone together with the variability in outcome 
measurements makes comparing these studies more complicated.  
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      None of these studies address other confounding factors such as the decision to hospitalize a child. 
Beyond a recommendation from the infant’s pediatrician, the decision to hospitalize a child is multi-
faceted. For example, the distance to the hospital or the ability of the guardian to provide adequate care 
for the child, are among the factors that influence the decision for parents to hospitalize their child.  
Further Studies 
       In order to improve the validity of the effectiveness between dexamethasone and epinephrine, 
more research is warranted. Based on the studies that have been appraised here, it is noted that two of 
the three studies have small sample populations. A sufficient study sample is necessary in order to 
draw statistically significant conclusions, and would magnify all the small changes in the patients’ 
outcomes.  Larger, multi-center studies including acute bronchiolitis cases, with varying degrees of 
severity, and a larger age range, are needed in order to determine the effects of corticosteroids.  As 
Bentur et al{{52 Bentur,L. 2005}} found, the pre-term subgroup had better outcomes with the 
dexamethasone and epinephrine therapy. A look into the subgroups of infants who respond better to 
corticosteroids, for possible biomarkers, that may include virus identification techniques, may prove 
invaluable. Although, there were no serious short-term adverse events among the infants that were 
involved in the reviewed studies, there is a need for more long-term research or follow-up to 
determine, if the study treatment may cause adrenal suppression, arrest of somatic growth, or 
neurodevelopmental delay. Adrenal suppression from exogenous corticosteroids is still a risk, 
however, in a short term course of corticosteroids, this type of suppression is likely to be only 
temporary. {{67 Zora,J.A. 1986}} 
      One of the weaknesses in bronchiolitis literature, is the lack of validated clinical scoring scales that 
are objective, replicable, and can be easily carried out in a variety of settings. Future studies should 
choose to evaluate clinically relevant outcomes. Most of the outcomes in this literature focus on short-
term measurements such as oxygen saturation or respiratory rate returning to baseline after treatment. 
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Investigators should focus more on the outcomes that matter to parents, clinicians, and health systems 
by measuring hospital admission or readmission rates, duration of hospital stay, costs of care, the level 
of parental satisfaction with treatment, and the development of future respiratory symptoms in the 
patient.  
      Additional research can follow the direction of Kuyucu et al{{40 Kuyucu,S. 2004}}, Bentur et 
al{{52 Bentur,L. 2005}}, and Plint et al{{48 Plint,Amy C. 2009}}, in determining a standardized 
dosing and administration of dexamethasone with epinephrine.  A future study should also follow a 
more consistent follow-up protocol, clear and precise documentation, and standardized outcome 
measurements.  
 
CONCLUSION 
 Emerging from the literature, there is evidence to suggest a positive synergistic effect between 
the combination therapy of dexamethasone with epinephrine in the treatment of bronchiolitis, and the 
decrease in morbidity, resulting in a shortened disease process. However, there is still insufficient 
evidence to support the use of this combination therapy until a larger, multi-centered trial is conducted. 
Although Plint et al{{48 Plint,Amy C. 2009}} was a large, multi-centered, randomized, placebo 
controlled trial, it did not expect to discover a relationship between dexamethasone and epinephrine 
which would effect the morbidity of bronchiolitis, and therefore, should be considered exploratory. 
Although, further studies are warranted, it is established that supportive care and close monitoring is 
valuable for children who present with an initial episode of wheezing. Therefore, confirmation of Plint 
et al{{48 Plint,Amy C. 2009}}, and the two smaller studies by Bentur et al{{52 Bentur,L. 2005}} and 
Kucuyu et al{{40 Kuyucu,S. 2004}}, by a study that is specifically designed to compare combined 
dexamethasone and epinephrine therapy with placebo is needed in order to definitively ascertain the 
differential effects of therapy as applied to the severity and phase of bronchiolitis. 
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Table 1. JADAD Score Calculation 
Item Score 
Was the study described as randomized (this includes 
words such as randomly, random, randomization)?  
0/1 
Was the method used to generate the sequence of 
randomization described and appropriate (table of 
random numbers, computer-generated, etc)?  
0/1 
Was the study described as double-blind? 0/1 
Was the method of double blinding described and 
appropriate (identical placebo, active placebo, dummy, 
etc)? 
0/1 
Was there a description of withdrawals and dropouts?  0/1 
Deduct one point if the method used to generate the 
sequence of randomization was described and it was 
appropriate (patients were allocated alternately, or 
according to date of birth, hospital number, etc)?  
0/1 
Deduct one point if the study was described as double 
blind but the method of blinding was inappropriate (e.g. 
comparison of tablet vs. injection with no double 
dummy).  
0/1 
 
Table 2. Summary of Reviwed Articles 
Author/  
Title/ 
Journal 
Yr.  
publishe
d 
Patients/  
Population 
Intervention Comparison Outcome(s) Study type Score (of 
5)/ 
Commen
ts 
Results 
Plint et 
al. {{48 
Plint,Am
y C. 
2009}} 
2009 800 infants 
(6 weeks to 
12 months) 
with 
bronchiolitis 
1. Nebulized 
EPI + oral 
DEX 
2. Nebulized 
EPI 
2. DEX  
3. Placebo 
Placebo Hospital 
admission 
within 7 
days of 
enrollment 
(the initial 
visit to the 
ED)  
Multi-center, 
double blind, 
RCT/ 
placebo-
controlled 
trial, with 22 
day follow 
up. 2004-
2007. 
5/5.  Combined 
therapy with 
DEX and EPI 
may 
significantly 
reduce hospital 
admissions. 
Bentur et 
al. {{52 
Bentur,L. 
2005}} 
2005 61 infants 
with 
bronchiolitis 
(3-12 
months)  
0.25 mg 
DEX with 1 
ml EPI 
nebulization 
q 6 hours 
Placebo (0.5 
ml Nebulized 
0.9% saline ) 
and 1ml EPI 
Length of 
inpatient 
hospital stay 
RCT. Double-
blind, placebo 
controlled 
study, with 3 
months 
follow up. 
Sept 2002-
4/5. No 
descriptio
n of 
withdraw
als 
Or 
dropouts.  
Inhaled DEX 
may reduce the 
length of  
hospitalization 
in combination 
with EPI 
nebulization.  
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March 2003 
Kuyucu 
et al. 
{{40 
Kuyucu,
S. 
2004}} 
2004 69 infants 
with 
bronchiolitis, 
outpatient 
setting. (2-21 
months)  
EPI and DEX 1. 
Salbutamol + 
placebo 
2. EPI + 
placebo 
Outcome 
measures: 
Heart rate, 
respiratory 
rate, RDAI.  
RCT. 
placebo-
controlled, 
prospective 
trial study 
5/5.  A single dose 
of IM DEX 
with nebulized 
L-EPI resulted 
in better 
outcome 
measures than 
bronchodilators 
alone in the 
late phase (5th 
day).  
 
EPI: Epinephrine; DEX: Dexamethasone; RCT: Randomized Controlled Trial: ED: Emergency Department: RDAI: 
Respiratory Distress Assessment Instrument; RACS: Respiratory Assessment Change Score 
 
Table 3. RDAI (Respiratory Distress Assessment Index)  
Symptom  Point scale 
Expiratory Wheezing 0-4 points 
Inspiratory Wheezing 0-2 points 
Location of Wheeze 0-2 points 
Supraclavicular retraction 0-3 points 
Intercostal retraction 0-3 points 
Subcostal retraction 0-3 points 
 
 
 
 
